Exploring Keros Therapeutics, Inc. (KROS) Investor Profile: Who’s Buying and Why?

Have you ever wondered who the major players are behind Keros Therapeutics, Inc. (KROS)? As of December 31, 2024, a total of 377 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a collective 41,075,883 shares. Institutional investors hold approximately 101.26% of the company's shares. The top institutional holders include Fmr Llc with 5.54M shares valued at $77,994,341, BlackRock, Inc. with 2.73M shares valued at $38,400,940, and Vanguard Group Inc with 1.96M shares worth $27,536,523. Why are these institutions investing, and what does it mean for the company's future?

Keros Therapeutics, Inc. (KROS) Who Invests in Keros Therapeutics, Inc. (KROS) and Why?

Understanding the investor profile of Keros Therapeutics, Inc. (KROS) involves examining the diverse range of entities and individuals who hold the company's stock, along with their motivations and strategies. This insight is crucial for current and potential investors, offering a clearer picture of the market dynamics influencing KROS.

Key Investor Types:

The investor base of Keros Therapeutics, Inc. (KROS) can be segmented into several key categories:

• Institutional Investors: These include investment companies, hedge funds, pension funds, and insurance companies. Institutional investors often hold a significant portion of a company's shares and can exert considerable influence on its stock price.
• Retail Investors: These are individual investors who buy and sell securities for their own accounts. While individual holdings may be smaller, the collective impact of retail investors can be substantial.
• Hedge Funds: These are investment partnerships that use pooled funds and employ various strategies to earn active return, or alpha, for their investors. Hedge funds often take more aggressive investment approaches.
• Corporate Insiders: These are the company's executives and board members who own shares. Their investment decisions are closely watched as they have intimate knowledge of the company's operations and prospects.

Investment Motivations:

Investors are drawn to Keros Therapeutics, Inc. (KROS) for a variety of reasons, typically revolving around the company's potential for growth and innovation in the biotechnology sector.

• Growth Prospects: Biotechnology companies like Keros Therapeutics, Inc. (KROS) often attract investors due to their high-growth potential. Successful clinical trials and FDA approvals can lead to significant increases in stock value.
• Market Position: A company's position within its specific market niche also influences investor interest. Keros Therapeutics, Inc. (KROS)'s focus on novel therapeutics might give it a competitive edge.

Investment Strategies:

The strategies employed by investors in Keros Therapeutics, Inc. (KROS) can vary widely depending on their investment goals and risk tolerance.

• Long-Term Holding: Many institutional investors adopt a long-term holding strategy, based on the belief that the company's value will appreciate over time. This approach is common among pension funds and large investment companies.
• Short-Term Trading: Hedge funds and some retail investors may engage in short-term trading, seeking to profit from short-term price fluctuations.
• Value Investing: Some investors may see Keros Therapeutics, Inc. (KROS) as undervalued by the market and invest based on the expectation that the company's true value will eventually be recognized.

Understanding the composition, motivations, and strategies of Keros Therapeutics, Inc. (KROS)'s investor base provides critical insights into the stock's behavior and potential future performance. Monitoring these factors can help investors make more informed decisions.

Keros Therapeutics, Inc. (KROS) Institutional Ownership and Major Shareholders of Keros Therapeutics, Inc. (KROS)

Institutional ownership in Keros Therapeutics, Inc. (KROS) reflects the degree of confidence that large financial organizations have in the company's potential. These institutions conduct extensive research before investing, making their involvement a noteworthy indicator for other investors. Examining the ownership structure can provide insights into market sentiment and potential stock performance. Here is detailed information regarding the institutional investors and major shareholders of Keros Therapeutics, Inc. (KROS).

As of March 31, 2024, Keros Therapeutics, Inc. (KROS) had a mix of institutional and retail investors. Recent data highlights significant institutional ownership. Let's explore who the major players are and how their investment activities might influence KROS.

Here’s what we know about Keros Therapeutics, Inc. (KROS)’s top institutional investors:

• Vanguard Group Inc.: As of March 31, 2024, Vanguard Group Inc. holds 2,284,286 shares, representing about $142,939,000 USD.
• BlackRock Fund Advisors: BlackRock Fund Advisors reported holding 1,783,134 shares valued at approximately $111,690,000 USD.
• FMR LLC: FMR LLC's holdings include 1,499,426 shares, with a total value of $93,891,000 USD.
• RA Capital Management, L.P.: RA Capital Management, L.P. holds 1,397,426 shares, worth around $87,508,000 USD.
• State Street Global Advisors, Inc.: State Street Global Advisors, Inc. owns 644,953 shares valued at $40,372,000 USD.

These major institutional investors collectively hold a significant percentage of Keros Therapeutics, Inc. (KROS)’s outstanding shares, indicating strong institutional interest in the company.

Changes in institutional ownership can provide valuable insights into the evolving sentiment around a stock. Analyzing recent changes in holdings of Keros Therapeutics, Inc. (KROS) can reveal whether institutional investors are becoming more or less bullish on the company.

Recent data indicates the following changes in ownership:

• Vanguard Group Inc.: Increased its holdings by 4.0% in the first quarter of 2024.
• FMR LLC: Increased its holdings by approximately 11.0% during the same period.
• BlackRock Fund Advisors: Showed a slight decrease in their holdings, adjusting their position by -0.1% in Q1 2024.

These changes suggest a dynamic environment with some institutions increasing their stakes while others slightly reduce theirs. Overall, the trend indicates sustained confidence from major institutional players.

The presence and activities of large institutional investors can significantly influence a company's stock price and overall strategy. Their actions can drive trading volume, impact valuation, and signal confidence (or lack thereof) to the broader market. Here’s how these investors can affect Keros Therapeutics, Inc. (KROS):

• Price Stability and Liquidity: Large institutional holdings typically provide more stability to the stock price and increase liquidity, making it easier for other investors to trade the stock.
• Signaling Effect: When prominent institutions increase their positions, it often sends a positive signal to the market, potentially attracting more investors and driving up the stock price.
• Influence on Corporate Strategy: Major shareholders can exert influence on company management and strategic decisions, especially if they coordinate their efforts.

Below is a detailed table that summarizes the ownership structure of Keros Therapeutics, Inc. (KROS), highlighting key institutional investors and their respective holdings as of Q1 2024:

Understanding the dynamics of institutional ownership in Keros Therapeutics, Inc. (KROS) is essential for investors looking to gain a deeper understanding of the company's market position and future prospects. The significant stakes held by major institutions, coupled with recent changes in their holdings, provide valuable signals about the stock's potential performance.

To gain further insights into Keros Therapeutics, Inc. (KROS), explore its history, mission, and business model here: Keros Therapeutics, Inc. (KROS): History, Ownership, Mission, How It Works & Makes Money

Keros Therapeutics, Inc. (KROS) Key Investors and Their Impact on [Company Name]

Understanding the investor profile of Keros Therapeutics, Inc. (KROS) is crucial for gauging market sentiment and potential stock performance. Key investors can significantly influence company decisions and stock movements through large stakes and strategic initiatives. Here’s a detailed look at notable investors in Keros Therapeutics, Inc. (KROS) and their recent activities.

While specific real-time data on all individual investors might fluctuate, examining institutional ownership provides valuable insights. Institutional investors typically include mutual funds, hedge funds, pension funds, and other large entities that manage investments on behalf of others. These institutions conduct thorough research before investing, and their actions can often signal confidence or concerns about a company’s prospects.

To provide a relevant picture of investor influence, we can analyze the types of institutional investors holding Keros Therapeutics, Inc. (KROS) stock:

• Mutual Funds: These funds pool money from many investors to purchase a diversified portfolio of stocks. Significant mutual fund ownership can indicate broad market confidence in Keros Therapeutics, Inc. (KROS).
• Hedge Funds: Known for employing more aggressive investment strategies, hedge funds often take large positions in companies they believe are undervalued or poised for growth. Their involvement can sometimes lead to activist strategies aimed at influencing company management.
• Pension Funds: These funds invest to provide retirement income for their members. Pension fund investments tend to be long-term, reflecting a stable outlook on Keros Therapeutics, Inc. (KROS).
• Other Institutional Investors: This category includes insurance companies, endowments, and other large organizations that invest for various purposes.

Investor influence at Keros Therapeutics, Inc. (KROS) can manifest in several ways:

• Shareholder Votes: Large investors have a significant say in company matters that require shareholder approval, such as electing board members, approving mergers, and executive compensation.
• Activist Campaigns: Some investors may launch public campaigns to push for specific changes in company strategy or governance.
• Private Negotiations: Major shareholders often engage in private discussions with management to influence decision-making.

Recent moves by key investors, such as buying or selling large stakes, are closely watched by the market. For instance, a substantial purchase by a well-known fund can boost investor confidence, while a large sell-off might raise concerns. Unfortunately, specifics can vary.

For further insights into Keros Therapeutics, Inc. (KROS)'s financial standing, see this analysis: Breaking Down Keros Therapeutics, Inc. (KROS) Financial Health: Key Insights for Investors

Keros Therapeutics, Inc. (KROS) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions is crucial for assessing the potential future of Keros Therapeutics, Inc. (KROS). Shifts in major shareholders' positions, market responses to these changes, and analyst perspectives all provide valuable insights.

As of February 13, 2024, Keros Therapeutics, Inc. (KROS) had a short float of 9.26%. The company's stock price has shown considerable movement, reflecting the dynamic nature of investor sentiment and market reactions. Recent data indicates a mix of institutional buying and selling, which can influence stock volatility.

Here's a look at some factors influencing investor sentiment:

• Ownership Changes: Significant changes in ownership by major institutional investors can signal shifts in confidence regarding Keros Therapeutics, Inc. (KROS)’s prospects.
• Market Performance: The stock's reaction to overall market trends and specific news related to Keros Therapeutics, Inc. (KROS) can reflect prevailing sentiment.
• Analyst Ratings: Analyst upgrades or downgrades can sway investor opinion and trigger buying or selling activity.

Recent market reactions include fluctuations following announcements related to clinical trial results and financial reports. For instance, positive clinical data often leads to increased investor confidence and a rise in stock price, while disappointing results can have the opposite effect.

Analyst perspectives play a vital role in shaping investor sentiment. Analysts provide insights based on their in-depth analysis of Keros Therapeutics, Inc. (KROS)’s financials, pipeline, and market opportunities. Their recommendations can influence both retail and institutional investors.

For example, analysts might focus on:

• Growth Potential: Assessments of Keros Therapeutics, Inc. (KROS)’s drug development pipeline and potential market for its products.
• Financial Health: Analysis of the company’s balance sheet, cash flow, and ability to fund ongoing research and development.
• Competitive Landscape: Evaluation of Keros Therapeutics, Inc. (KROS)’s position relative to its competitors and the broader biotech industry.

To provide a clearer picture of Keros Therapeutics, Inc. (KROS)'s investor profile, consider the following hypothetical overview:

Keep in mind that this is a general overview, and specific sentiments and impacts can change rapidly based on new information and market dynamics.

Examining the interplay between investor sentiment, market reactions, and analyst perspectives provides a well-rounded understanding of the forces shaping Keros Therapeutics, Inc. (KROS)’s market performance. For more insights into the company's foundational principles, explore Mission Statement, Vision, & Core Values of Keros Therapeutics, Inc. (KROS).